Explore our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts.

Sign in Join

July 21 – 27, 2025

Psychedelic Bulletin #204

Psychedelic Alpha ↗

  • FDA Keeps GH Research’s 5-MeO-DMT on Ice as atai and Beckley Surge Ahead
  • Makary’s Priority Voucher Program Launches, Cites Novel PTSD Treatment as Example
  • HALT Fentanyl Act Signed by Trump, Could Streamline Schedule I Researcher Registration for Some
  • FDA AdComm Skewers PTSD Drug Combo
  • Czech President Signs Medical Psilocybin Into Law
  • Psychedelic Stocks Surge, Compass Recovers from Readout Sell-off
  • New Zealand’s Medicines Regulator Publishes Guidance for Practitioners Applying to Prescribe Psychedelics
  • Psilocybin for Stroke Study Launches at Hopkins
  • Spravato Sales Continue to Increase
  • and more…

July 14 – 20, 2025

Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD; Longevity Crowd Hypes Psilocybin Study; Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch?

Psychedelic Bulletin #203

Psychedelic Alpha ↗

  • Norway’s Health System Considers Funding Off-Label Ketamine for Treatment-Resistant Depression
  • Spravato’s Monotherapy Success Puts Pressure on Psychedelics Developers
  • Longevity Crowd Hypes Psilocybin Study But Researchers Urge Caution
  • Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch?
  • Three Years of Psychedelics Access via Canada’s Special Access Programme
  • The New Neuroplastogen Developer on the Block
  • and more…

↗

July 7 – 13, 2025

June 30 – July 6, 2025

Oregon Psilocybin Services Tracker_ Q1 2025

Q1 2025: Oregon Psilocybin Services Tracker

Psychedelic Alpha ↗

As the first cut of data from Oregon’s psilocybin program becomes available, we take a deep dive into emerging trends through various data visualisations and analysis. This marks the first instalment of our new Oregon Psilocybin Services Tracker, which will produce analysis of each cut of data as it is released.

Pα+

An insider’s guide to the business,
policy and science of psychedelics.

Basic

Free subscribers receive a weekly round-up
of news on psychedelics, as well as the occasional article.

Receive regular bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments.

Monthly $20 Annually $200

Teams

Teams, groups and corporate pricing plans are available, please get in touch via email
to learn more.

Benefits

Front-row access to the psychedelics space: breaking bulletins, in-depth articles, insider interviews and sharp analysis of the moments that matter—from major trial results and funding rounds to policy shifts shaping the future. Plus, full access to our complete
archive and Library.

Learn More
  Free
Weekly Psychedelic News Feed
Occasional Articles & Free Resources
Psychedelic Bulletins (In-Depth Briefings, Multiple per Month)
Quick-Take Analysis of Major Developments
In-Depth Articles & Deep Dives
Exclusive Interviews with Insiders & KOLs
Quarterly Video Briefings
Exclusive Tools & Data Resources
Library of Primers & Explainers

Subscribe Now

Monthly $20 Annually $200

Join Today

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.

Monthly $20 Annually $200

Subscribe to our
free newsletter


By signing up, you agree to our privacy policy. You can unsubscribe at any time.

Learn More About

Group, team &
corporate plans


Aside from group pricing, we also offer bespoke reports and regular briefings. Get in touch to discuss.